Literature DB >> 24973212

Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.

Jan Sommer1, Christoph Garbers2, Janina Wolf2, Ahmad Trad2, Jens M Moll1, Markus Sack3, Rainer Fischer3, Joachim Grötzinger2, Georg H Waetzig4, Doreen M Floss1, Jürgen Scheller5.   

Abstract

Interleukin (IL)-6 signals via a receptor complex composed of the signal-transducing β-receptor gp130 and the non-signaling membrane-bound or soluble IL-6 receptor α (IL-6R, sIL-6R), which is referred to as classic and trans-signaling, respectively. IL-6 trans-signaling is functionally associated with the development of chronic inflammatory diseases and cancer. Soluble gp130 (sgp130) variants are natural inhibitors of trans-signaling. Differential splicing yields sgp130 isoforms. Here, we describe that alternative intronic polyadenylation in intron 10 of the gp130 transcript results in a novel mRNA coding for an sgp130 protein isoform (sgp130-E10) of 70-80 kDa. The sgp130-E10 protein was expressed in vivo in human peripheral blood mononuclear cells. To assess the biological activity of sgp130-E10, we expressed this variant as Fc-tagged fusion protein (sgp130-E10Fc). Recombinant sgp130-E10Fc binds to a complex of IL-6 and sIL-6R, but not to IL-6 alone, and specifically inhibits IL-6 trans-signaling. Thus, it might play an important role in the regulation of trans-signaling in vivo.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Alternative Splicing; Interleukin; Polyadenylation; Protein-tyrosine Kinase (Tyrosine Kinase); Signal Transduction

Mesh:

Substances:

Year:  2014        PMID: 24973212      PMCID: PMC4139227          DOI: 10.1074/jbc.M114.560938

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

2.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

Authors:  R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

3.  Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis.

Authors:  M Tanaka; M Kishimura; S Ozaki; F Osakada; H Hashimoto; M Okubo; M Murakami; K Nakao
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 4.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

5.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.

Authors:  T Jostock; J Müllberg; S Ozbek; R Atreya; G Blinn; N Voltz; M Fischer; M F Neurath; S Rose-John
Journal:  Eur J Biochem       Date:  2001-01

6.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

Authors:  M Narazaki; K Yasukawa; T Saito; Y Ohsugi; H Fukui; Y Koishihara; G D Yancopoulos; T Taga; T Kishimoto
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

7.  Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos.

Authors:  A M Sharkey; K Dellow; M Blayney; M Macnamee; S Charnock-Jones; S K Smith
Journal:  Biol Reprod       Date:  1995-10       Impact factor: 4.285

8.  The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases.

Authors:  Christoph Garbers; Niloufar Monhasery; Samadhi Aparicio-Siegmund; Juliane Lokau; Paul Baran; Mari A Nowell; Simon A Jones; Stefan Rose-John; Jürgen Scheller
Journal:  Biochim Biophys Acta       Date:  2014-05-27

Review 9.  Smart drugs: tyrosine kinase inhibitors in cancer therapy.

Authors:  Laura K Shawver; Dennis Slamon; Axel Ullrich
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

10.  Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.

Authors:  Stephanie Tenhumberg; Georg H Waetzig; Athena Chalaris; Björn Rabe; Dirk Seegert; Jürgen Scheller; Stefan Rose-John; Joachim Grötzinger
Journal:  J Biol Chem       Date:  2008-07-23       Impact factor: 5.157

View more
  11 in total

1.  Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation.

Authors:  Tingting Weng; Junsuk Ko; Chioniso P Masamha; Zheng Xia; Yu Xiang; Ning-Yuan Chen; Jose G Molina; Scott Collum; Tinne C Mertens; Fayong Luo; Kemly Philip; Jonathan Davies; Jingjing Huang; Cory Wilson; Rajarajan A Thandavarayan; Brian A Bruckner; Soma Sk Jyothula; Kelly A Volcik; Lei Li; Leng Han; Wei Li; Shervin Assassi; Harry Karmouty-Quintana; Eric J Wagner; Michael R Blackburn
Journal:  J Clin Invest       Date:  2019-02-28       Impact factor: 14.808

2.  Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19.

Authors:  María Ángeles Rodríguez-Hernández; David Carneros; María Núñez-Núñez; Ramón Coca; Rosario Baena; Gema M López-Ruiz; María Elena Cano-Serrano; Alberto Martínez-Tellería; Ana Fuentes-López; Juan Manuel Praena-Fernandez; Christoph Garbers; José Hernández-Quero; Federico García; Stefan Rose-John; Matilde Bustos
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

3.  Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.

Authors:  Janina Wolf; Georg H Waetzig; Athena Chalaris; Torsten M Reinheimer; Henning Wege; Stefan Rose-John; Christoph Garbers
Journal:  J Biol Chem       Date:  2016-05-23       Impact factor: 5.157

4.  Cortical bone maturation in mice requires SOCS3 suppression of gp130/STAT3 signalling in osteocytes.

Authors:  Emma C Walker; Kim Truong; Narelle E McGregor; Ingrid J Poulton; Tsuyoshi Isojima; Jonathan H Gooi; T John Martin; Natalie A Sims
Journal:  Elife       Date:  2020-05-27       Impact factor: 8.140

5.  Alternative Polyadenylation Modification Patterns Reveal Essential Posttranscription Regulatory Mechanisms of Tumorigenesis in Multiple Tumor Types.

Authors:  Min Li; XiaoYong Pan; Tao Zeng; Yu-Hang Zhang; Kaiyan Feng; Lei Chen; Tao Huang; Yu-Dong Cai
Journal:  Biomed Res Int       Date:  2020-06-15       Impact factor: 3.411

6.  Expression of Interleukin 6 signaling receptors in carotid atherosclerosis.

Authors:  Louise Ziegler; Jasmin Lundqvist; Kristian Dreij; Håkan Wallén; Ulf de Faire; Gabrielle Paulsson-Berne; Ulf Hedin; Ljubica Matic; Bruna Gigante
Journal:  Vasc Med       Date:  2020-12-22       Impact factor: 3.239

7.  Exclusive inhibition of IL-6 trans-signaling by soluble gp130FlyRFc.

Authors:  Anna F Berg; Julia Ettich; Hendrik T Weitz; Matthias Krusche; Doreen M Floss; Jürgen Scheller; Jens M Moll
Journal:  Cytokine X       Date:  2021-11-29

Review 8.  Alternative Splicing: A New Cause and Potential Therapeutic Target in Autoimmune Disease.

Authors:  Pingping Ren; Luying Lu; Shasha Cai; Jianghua Chen; Weiqiang Lin; Fei Han
Journal:  Front Immunol       Date:  2021-08-17       Impact factor: 7.561

9.  Pleiotropic, Unique and Shared Responses Elicited by IL-6 Family Cytokines in Human Vascular Endothelial Cells.

Authors:  Madelene Lindkvist; Mulugeta M Zegeye; Magnus Grenegård; Liza U Ljungberg
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

10.  A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 trans-Signaling and Cellular Infection with SARS-CoV-2.

Authors:  Julia Ettich; Julia Werner; Hendrik T Weitz; Eva Mueller; Roland Schwarzer; Philipp A Lang; Jürgen Scheller; Jens M Moll
Journal:  J Virol       Date:  2021-12-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.